Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients
Authors:
Open Access
- 25 July 2024
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 38 (7) , e15340
Abstract
Background & aims: Severe alcohol‐associated hepatitis (SAH) represents a lethal subset of alcohol‐associated liver disease. Although corticosteroids are recommended by guidelines, their efficacy and safety remain questionable and so liver transplantation (LT) has been increasingly utilized. The timing and indication of corticosteroid use, specifically in patients being considered for LT requires further clarification.Methods: A retrospective analysis was conducted on 256 patients with SAH between 2018 and 2022 at a single US center.Results: Twenty of these patients underwent LT. Of the 256 patients, 38% had what we termed “catastrophic” SAH, defined as a MELD‐Na ≥35 and/or discriminant function (DF) ≥100, which carried a mortality of 90% without LT. Compared with 100 matched controls, patients undergoing LT exhibited a one‐year survival rate of 100% versus 35% (p < .0005). LT provided an absolute risk reduction of 65%, with a number needed to treat of 1.5. Steroid utilization in the entire cohort was 19% with 60% developing severe complications. Patients administered steroids were younger with lower MELD and DF scores. Only 10% of those prescribed steroids derived a favorable response. Sustained alcohol use post‐LT was 20%.Conclusions: We propose ELFSAH: Expedited LT as First Line Therapy for SAH; challenging the current paradigm with recommendations to defer steroids in patients with “catastrophic” SAH (defined as: MELD‐Na ≥35 and/or DF ≥100). Patients should be seen urgently by hepatology, transplant surgery, psychiatry and social work. Patients without an absolute contraindication should be referred for LT as first‐line therapy during their index admission.Keywords
This publication has 34 references indexed in Scilit:
- Early living donor liver transplantation for alcohol-associated hepatitisAnnals of Hepatology, 2023
- Black patients and women have reduced access to liver transplantation for alcohol‐associated liver diseaseLiver Transplantation, 2022
- Debate on Selection Criteria for Liver Transplantation for Alcoholic Hepatitis: Tighten or Loosen?Liver Transplantation, 2020
- Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated HepatitisLiver Transplantation, 2019
- Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver DiseasesHepatology, 2019
- Good outcome of living donor liver transplantation for severe alcoholic hepatitis not responding to medical management: A single center experience of 39 patientsAlcohol, 2019
- Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016JAMA, 2019
- Steroids for Severe Alcoholic Hepatitis: More Risk Than Reward?Clinical Liver Disease, 2018
- Early liver transplantation for severe alcoholic hepatitisClinical Liver Disease, 2018
- The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroidsHepatology, 2007